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Abstract 8 
Background: 9 
D-dimers have a high negative predictive value for excluding venous 10 
thromboembolism  outside of pregnancy but the use in pregnancy remains 11 
controversial. A higher cut-off value has been proposed in pregnancy due to a 12 
continuous increase across gestation. Fibrin monomer complexes have been 13 
considered as an alternative diagnostic tool for exclusion of VTE in pregnancy due to 14 
their different behaviour. 15 
Objective: To establish normal values of Fibrin monomer complexes and D-dimer as 16 
a diagnostic tool for the exclusion of VTE in pregnancy and examine the effect of 17 
maternal and obstetric factors on these markers. 18 
Study Design: Plasma D-dimer and fibrin monomer complexes were measured by 19 
quantitative immunoturbidimetry in 2870 women with singleton pregnancies 20 
attending for their routine first trimester hospital visit in a prospective screening study 21 
for adverse obstetric outcome. Multiple regression analysis was used to determine 22 
maternal characteristics and obstetric factors affecting the plasma concentrations 23 
and converting these into multiple of the median values after adjusting for significant 24 
maternal and obstetric characteristics. 25 
Results: Plasma fibrin monomer complexes increased with maternal weight and 26 
were lower in women with a history of cocaine abuse and chronic hypertension.D-27 
dimers increased with gestational age and maternal weight and were higher in sickle 28 
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cell carriers and in women of African and South Asian racial origin compared to 1 
Caucasians.  2 
Conclusions: Fibrin monomer complexes and D-dimers are affected by maternal 3 
and obstetric characteristics rather than only gestational age. The utility of these 4 
fibrin-linked markers as a  tool for exclusion of venous thromboembolism in 5 
pregnancy might be improved by adjusting for patient specific characteristics.  6 
 7 
Key words: Fibrin monomer complex, D-dimer, Pregnancy, Screening ,venous 8 
thromboembolism 9 
 10 
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 1 
 2 
 3 
Introduction 4 
 5 
Pregnancy is a hypercoagulable state exemplifying Virchow’s triad of altered 6 
coagulation, stasis and vascular damage 1. VTE is one of the leading causes of 7 
maternal death in developed countries with about 1-2 deaths per 100 000 maternities 8 
or 9% of all maternal deaths in the United States2,3. The incidence of VTE in 9 
pregnancy is 1-2 per 1000, fivefold higher than in non–pregnant women 4. The 10 
antenatal risk for VTE is highest in the first and third trimester5 and in the UK the 11 
majority of antenatal deaths occurred in the first trimester 6.  12 
 13 
Outside of pregnancy, diagnostic pathways for DVT and PE are based on a 14 
combination of clinical scoring systems, blood tests and imaging using compression 15 
ultrasound (CUS), ventilation-perfusion (V/Q) scans or computed tomography 16 
pulmonary angiography (CTPA) 7. Both V/Q scans and CTPA are considered safe 17 
but concerns remain about fetal radiation and breast radiation exposure respectively 18 
with these modalities8.  19 
In pregnancy there are no clinically validated scoring systems and the clinical 20 
presentation can be confused with features of a healthy pregnancy9.  21 
D-dimer (DD)  is integral to diagnostic pathways outside of pregnancy and in 22 
individuals with low clinical probability has a high negative predictive value for VTE 23 
10
. Another marker of thrombin activation is the fibrin monomer (FM), an intermediate 24 
in cross-linked fibrin formation. FM are produced when thrombin proteolyses 25 
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fibrinogen into  fibrinopeptides A and B and FM.In prothrombotic conditions like 1 
disseminated intravascular coagulation syndrome (DIC) soluble complexes may be 2 
formed when FM join with fibrinogen and fibrin degradation products11 3 
D-dimers are produced by lysis of cross-linked fibrin and are therefore downstream 4 
from FM in this pathway. However DD levels normally rise in pregnancy and higher 5 
cut-off value have been proposed12There is evidence that DD and FM might behave 6 
differently in clinical scenarios, possibly reflecting the different stages of thrombin 7 
activation and fibrinolysis. For instance, there are small studies showing that 8 
changes in FM concentrations in uncomplicated pregnancy seem to be minimal 9 
compared to other haemostatic markers and FM are therefore considered an 10 
alternative tool for exclusion of VTE in pregnancy 13,14. 11 
 12 
It would be desirable to be able to utilise fibrin-linked markers within pregnancy to 13 
help exclude the likelihood of VTE and reduce the requirement for imaging as shown 14 
for the use of FM outside pregnancy15. 16. Further, it is likely that characteristics of 15 
the mother as well as the pregnancy might also affect haemostatic markers. The 16 
objectives of this screening study at 11-13 weeks’ gestation are to establish a 17 
reference range for plasma FM and DD and examine the maternal and pregnancy 18 
characteristics that affect the measurements. 19 
 20 
 21 
Materials and Methods 22 
 23 
Study population 24 
The data for the study were derived from prospective screening for adverse obstetric 25 
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outcomes in women attending for their routine hospital visit in the first-trimester of 1 
pregnancy at King’s College Hospital, London, between October 2011 and May 2 
2012. This visit, which was held at 11+0-13+6 weeks’ gestation, included recording of 3 
maternal characteristics and medical history, ultrasound examination for 4 
measurement of fetal crown-rump length (CRL), diagnosis of fetal abnormalities and 5 
measurement of fetal nuchal translucency thickness as part of combined screening 6 
for fetal trisomies17. Venous blood (4 mL) was obtained from the antecubital vein and 7 
collected into tubes containing liquid 0.109M trisodium citrate (BD Medical Systems, 8 
Franklin Lakes, NJ, USA).  9 
 10 
Written informed consent was obtained from the women agreeing to participate in 11 
the study, which was approved by the Ethics Committee of the hospital. The 12 
pregnancies included in the study were those resulting in live birth or stillbirth of 13 
phenotypically normal babies at >24 weeks’ gestation. Women on current 14 
anticoagulation were excluded. 15 
 16 
Patient characteristics  17 
Patient characteristics recorded included maternal age, racial origin (Caucasian, 18 
Afro-Caribbean, South Asian, East Asian and mixed), method of conception 19 
(spontaneous or assisted conception requiring the use of ovulation drugs), cigarette 20 
smoking during pregnancy, medical history of chronic hypertension, diabetes 21 
mellitus,  sickle cell trait and autoimmune disease, including systemic lupus 22 
erythematosus or rheumatoid arthritis, family history of thromboembolic events and 23 
obstetric history including parity (parous or nulliparous if no previous pregnancies at 24 
> 24 weeks’ gestation). The maternal weight and height were measured. 25 
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 1 
Sample analysis 2 
The blood samples were processed within one hour after collection. After 3 
centrifugation at 2200g for 15 minutes at 20ºC the undiluted plasma has been 4 
analysed immediately in the STA-Compact® coagulation analyser (Diagnostica 5 
Stago, Asnieres Sur Seine, France) by quantitative immunoturbidimetry following the 6 
manufacturer’s instructions. We used STA®-Liatest® FM (Diagnostica Stago) and 7 
STA®-Liatest® DD (Diagnostica Stago) assays with respective working ranges of 5 - 8 
150 µg/mL and 0.22- 4.0 µg /mL, and an expected normal threshold in the adult non-9 
pregnant population of <6 µg/mL for fibrin monomers  and <0.5 µg/mL (expressed in 10 
FEU) for D-dimer. The intra-assay coefficient of variation [CV] and inter-assay CV were 11 
5.55 %, 5.7% for FM  and 8.4%,10.3% for DD, respectively 12 
 13 
Pregnancy outcome 14 
Data on pregnancy outcome were collected from the hospital maternity records or 15 
the general medical practitioners of the women. The birth weight percentile for 16 
gestational age at delivery was derived from a reference range for our population18. 17 
The definition of preeclampsia was that of the International Society for the Study of 18 
Hypertension in Pregnancy 19. Diagnosis of GDM was based on a 75-g oral glucose 19 
tolerance test performed at 24-28 weeks’ gestation20. 20 
 21 
Statistical analysis 22 
Data for continuous variables are presented as median (interquartile range) and data 23 
for categorical variables are presented as n (%). The observed values of serum DD 24 
and FM concentrations were log10 transformed to make their distributions Gaussian. 25 
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Normality was assessed using histograms and probability plots. Univariable 1 
regression analysis was used to examine the individual variables contributing 2 
significantly to prediction of log10 transformed values of DD and FM. Multivariable 3 
regression analysis with backward stepwise regression analysis was used to 4 
determine the significance of contribution from maternal and pregnancy 5 
characteristics. The measured concentration of DD and FM were converted into 6 
multiple of the median (MoM) values after adjusting for maternal characteristics that 7 
significantly affected log10 transformed values in the multiple regression analysis. 8 
The statistical software package SPSS 21 (SPSS Inc., Chicago,Ill., USA ) was used 9 
for data analyses. 10 
 11 
Results 12 
 13 
Study population 14 
During the study period we examined 2,870 singleton pregnancies with a live fetus at 15 
11-13 weeks, but 256 were excluded because of the pregnancy resulted in 16 
miscarriage or termination for fetal abnormalities and those with major fetal defects 17 
(n=107), anticoagulation therapy (n=28) or no pregnancy follow up (n=121). The 18 
characteristics of the study population of 2,614 pregnancies are shown in Table 1. In 19 
keeping with the South East London population, 61.7% women were of Caucasian 20 
origin, 27.9% Afro-Caribbean and 10.5% of other ethnic origins. D-dimers were 21 
measured in all cases but FM was measured in only 1286 of the cases due to 22 
reagent availability. 23 
 24 
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Fibrin-Monomer Complex 1 
The median, 5th and 95th percentiles of the measured FM concentration was 4.3, 2 
2.16 and 8.84 mg/L, respectively. In 282 (21.9%) of the 1,286 pregnancies the 3 
values were >6 mg/L. 4 
 5 
Univariable regression analysis demonstrated that significant contributions to log10 6 
FM were provided by several maternal and pregnancy characteristics (Table 3). 7 
Multivariable regression analysis demonstrated that significant contributions to log10 8 
FM were provided by maternal weight, cocaine use and medical history of chronic 9 
hypertension (Figure 1). 10 
 11 
The median and 5th, 10th, 90th and 95th percentiles, with 95% confidence intervals for 12 
FM MoM, were 0.99 (0.96 to 1.00) and 0.50 (0.45 to 0.53), 0.61 (0.57 to 0.64), 1.65 13 
(1.58 to 1.74) and 2.01 (1.88 to 2.17), respectively (Figure 2).  14 
 15 
D-Dimer 16 
The median, 5th and 95th percentiles of the measured DD concentration was 0.31, 17 
0.11 and 1.16 mg/L, respectively. In 736 (28.2%) of the 2,614 pregnancies the 18 
values were >0.5 mg/L. 19 
Univariable regression analysis demonstrated that significant contributions to log10 20 
DD were provided by several maternal and pregnancy characteristics (Table 2). 21 
Multivariable regression analysis demonstrated that significant contributions to log10 22 
DD were provided by gestational age, maternal weight, smoking, maternal ethnic 23 
origin and medical history of sickle cell trait (Figure 1). 24 
 25 
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The median and 5th, 10th, 90th and 95th percentiles, with 95% confidence intervals for 1 
DD MoM, were 0.98 (0.96 to 1.00) and 0.37 (0.34 to 0.39), 0.47 (0.46 to 0.49), 2.23 2 
(2.09 to 2.34) and 2.93 (2.73 to 3.18), respectively (Figure 2).  3 
 4 
Comment 5 
This study has established a reference range for serum FM and DD in singleton 6 
pregnancies at 11-13 weeks’ gestation and reports the maternal and pregnancy 7 
characteristics that affect the measurements. The study also illustrates that the cut-8 
offs of 6 mg/L for FM and 0.5 mg/L for DD used for exclusion of VTE in non-pregnant 9 
individuals are not applicable to pregnancy because these values were already 10 
exceeded by the end of the first trimester in 22% and 28% of cases, respectively. 11 
 12 
Multivariable regression analysis demonstrated that the level of FM increased with 13 
maternal weight and was decreased in women with chronic hypertension and those 14 
reporting use of cocaine. The level of DD increases with gestational age and 15 
maternal weight and is higher in those with sickle cell trait. D-dimer is increased in 16 
women of Afro-Caribbean and South Asian racial origin relative to Caucasians, and it 17 
is decreased in cigarette smokers. We also examined the association with 18 
pregnancy outcomes: levels of DD and FM at 11 to 13 weeks gestation were not 19 
significantly altered in pregnancies that subsequently developed preeclampsia, fetal 20 
growth restriction or gestational diabetes mellitus. 21 
 22 
Strengths and limitations: 23 
The strengths of this first-trimester study are firstly, examination of a large population 24 
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of pregnant women attending for routine care in a gestational age range which is 1 
widely used for screening for pregnancy complications; secondly, measurement of 2 
maternal serum concentration of fibrin-linked markers that have been shown to be 3 
altered in VTE and thirdly, expression of the values as MoMs after adjustment for 4 
factors that affect the measurements.  5 
 6 
One limitation of the study is that despite the fact that all women were clinically free 7 
from signs or symptoms of VTE at the time of testing, we did not exclude the 8 
possibility of asymptomatic VTE. This potential complication could have been 9 
avoided by conducting CUS of the lower extremities in all women. However, this 10 
technique has been validated only for the diagnosis of DVT in symptomatic women, 11 
rather than for the diagnosis of VTE in asymptomatic women. Consequently, in 12 
selecting our study population we relied on clinical signs and symptoms at the time 13 
of recruitment and in obtaining postpartum data on all pregnancy complications. A 14 
further limitation is that absolute plasma values and cut-offs are not exactly 15 
comparable between different assay types and methodologies and also depend on 16 
the instrument type; this paper only describes the relevant values and ranges 17 
pertaining to the STA-Liatest FM and DD as performed by our laboratory.  18 
 19 
 20 
Interpretation: 21 
In our study the median FM at 11-13 weeks’ gestation was 4.3 mg/L. Three previous 22 
studies examined FM levels in the first-trimester of normal pregnancy; the number of 23 
patients examined were 4321,3313 and 3622 and the reported median FM was 2.3, 3.4 24 
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and 4.3 mg/L, respectively ,. Onishi and Joly also used the STA Liatest FM and the 1 
FM concentrations were comparable to our data. 2 
 3 
In our study using the STA-Liatest assays, the median DD at 11-13 weeks’ gestation 4 
was 0.31 mg/L. Several previous studies in small numbers of cases ranging from 5 5 
to 350 normal pregnancies at <16 weeks’ gestation, reported that the median DD 6 
varied between 0.1 and 0.8 mg/L13,12,22,23,24,25,26,27,28,29,30,31,32,33,34,24. For the STA-7 
Liatest assay we found in the literature first trimester concentrations of 0.3mg/L21, 8 
0.49 mg/L 28,0.2 mg/L in a Chinese population 26 and 0.48 mg/L in women without 9 
DVT and 5.4mg/L with confirmed DVT 30. 10 
 11 
 12 
None of the previous studies in pregnant women on either FM or DD examined the 13 
possible association of levels with maternal demographic characteristics. However, a 14 
study in 4,364 mainly non-pregnant individuals presenting to a medical emergency 15 
department examined the effect of patient characteristics on DD level and reported 16 
significant positive associations with several factors including black race, cocaine 17 
use, rheumatoid arthritis, SLE and sickle cell trait 35. 18 
 19 
Our finding of increasing levels of both FM and DD with maternal weight might reflect 20 
the increased susceptibility of obese women to VTE 36. Maternal obesity is also 21 
histopathologically associated with chronic villitis and fetal thrombosis. 37  22 
Similarly the association of increased levels of DD in women of Afro-Caribbean racial 23 
origin is compatible with the increased susceptibility of these women to VTE 38. It is 24 
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possible that there might be ethnic differences in the regulation of proteins in the 1 
coagulation cascade; a further example is the elevated levels of factor VIII in the 2 
black population, both in normal subjects and those with VTE, relative to those of 3 
Caucasian origin39. 4 
Individuals with sickle cell trait have an association with increased coagulation activity but 5 
the mechanism is not well understood40. 6 
Pregnant women with increased BMI, sickle cell carriers and African and South 7 
Asian origin have elevated and smokers decreased DD-MoMs.The utility of this 8 
finding in improving diagnostic performance of DD has to be evaluated in future 9 
studies including pregnant women with confirmed VTE. 10 
At present we can only speculate why FM behave differently than DD and are 11 
negatively affected by chronic hypertension and cocaine use. A subanalysis of the 12 
women with FM concentrations above the 95th percentile showed that the median 13 
DD concentration in this group was 0,44 mg/L and therefore not similarly high.FM 14 
were not affected by the analysed pregnancy complications but lower in women with 15 
chronic hypertension and cocaine use,both conditions associated with 16 
vasoconstriction,smaller placental size and placental abruption41.Platelet activation 17 
through the 5HT pathway independent of thrombin formation is an underlying 18 
mechanism linked to both conditions 42 43 44.Decreased FM may also reflect impaired 19 
maternal-placental attachment45 and at term fibrinogen predicts adverse maternal or 20 
neonatal outcomes in patients with placental abruption46 21 
Several previous studies have reported elevated DD levels in women with 22 
established preeclampsia and one study showed elevated DDs in women with a 23 
history of pre-eclampsia outside of pregnancy 47,48,49; hypercoagulability and 24 
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increased fibrin deposition has been proposed as an underlying mechanism. Our 1 
finding, that DDs were not significantly altered at 11-13 weeks in women that 2 
subsequently develop preeclampsia, suggests that such activity may not precede the 3 
clinical onset of the disease and is certainly not present from the first trimester.  4 
 5 
 6 
Conclusion: 7 
By contributing to the establishment of a reference range for STA-Liatest FM and DD 8 
and identifying the maternal characteristics that affect these markers at 11-13 weeks 9 
we open the possibility of using fibrin linked markers as a diagnostic screening tool 10 
for VTE in pregnancy. Further, the traditional approach to thromboprophylaxis in 11 
pregnancy is to identify the high-risk group for VTE from maternal characteristics and 12 
medical history, including previous VTE, increased maternal age and BMI, assisted 13 
conception and preeclampsia50,2. An integrated first hospital visit at 11 to 13 weeks 14 
during which data from maternal characteristics and history is combined with findings 15 
of biophysical and biochemical tests can already define the patient-specific risk for a 16 
wide spectrum of pregnancy complications, including fetuses with aneuploidy, 17 
miscarriage and fetal death, preterm delivery, preeclampsia, gestational diabetes, 18 
fetal growth restriction and macrosomia 17,51.  A similar approach of early pregnancy 19 
risk assessment might have the potential to be applied to VTE risk assessment too. 20 
Future studies might investigate how risk scoring and prevention of VTE might be 21 
improved by this new approach to pregnancy care. 22 
 23 
 24 
 25 
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 7 
Table 1. Maternal and pregnancy characteristics in the study population 8 
 9 
Maternal and pregnancy characteristics Study population (n=2,614) 
Maternal characteristics  
Maternal age in years, median (IQR) 32.0 (28.1 to 35.5) 
Maternal weight in Kg, median (IQR) 66.5 (59.3 to 77.0) 
Maternal height in meters, median (IQR) 1.65 (1.60 to 1.69) 
Gestational age in weeks, median (IQR) 12.7 (12.3 to 13.0) 
Cigarette smoker, n (%) 197 (7.5) 
Cocaine use, n (%) 15 (0.6) 
Racial origin  
Caucasian, n (%) 1,612 (61.7) 
Afro-Caribbean, n (%) 728 (27.9) 
South Asian, n (%) 121 (4.6) 
East Asian, n (%) 72 (2.8) 
Mixed, n (%) 81 (3.1) 
Conception  
Spontaneous, n (%) 2,518 (96.3) 
Assisted, n (%) 96 (3.7) 
Medical disorder  
Sickle cell trait, n (%) 90 (3.4) 
Thyroid disorders, n (%) 47 (1.8) 
Chronic hypertension, n (%) 54 (2.1) 
Autoimmune disease, n (%) 4 (0.2) 
Diabetes mellitus, n (%) 25 (1.0) 
Family history  
History of preeclampsia in mother 94 (3.6) 
Diabetes mellitus 371 (14.2) 
Obstetric history  
Nulliparous, n (%) 1,223 (46.8) 
Parous – previous preeclampsia, n (%) 102 (3.9) 
Parous – previous gestational diabetes, n (%) 21 (0.8) 
Current pregnancy complication  
Preeclampsia, n (%) 62 (2.4) 
Gestational diabetes, n (%) 82 (3.1) 
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 1 
IQR=interquartile range 2 
3 
Fetal growth restriction, n (%) 281 (10.7) 
Pregnancy outcome  
Gestation at delivery in weeks, median (IQR) 40.0 (39.0 to 40.9) 
Birth weight in grams, median (IQR) 3390 (3080 to 3696) 
Birth weight in percentile, median (IQR) 40.0 (39.0 to 40.9) 
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Table 2. Univariable and multivariable regression analysis to examine factors from maternal 1 
and pregnancy characteristics affecting the concentration of log10 transformed D-dimer  2 
 3 
 4 
CI=confidence interval  5 
6 
Variable 
Univariable analysis Multivariable analysis 
Estimate (95% CI) P value Estimate (95% CI) P value 
 
    
Maternal characteristics     
Maternal age in years - 32 -0.001 (-0.003 to 0.001) 0.303   
Maternal weight in Kg - 69 0.002 (0.002 to 0.003) <0.0001 0.001 (0.001 to 0.002) <0.0001 
Maternal height in meters -1.64 0.029 (-0.134 to 0.192) 0.727   
Gestational age in weeks - 11 0.061 (0.043 to 0.079) <0.0001 0.054 (0.036 to 0.071) <0.0001 
Cigarette smoker -0.072 (-0.113 to -0.030) 0.001 -0.057 (-0.096 to -0.017) 0.005 
Cocaine use -0.108 (-0.251 to 0.036) 0.142   
Racial origin     
Caucasian (reference) 1.000    
Afro-Caribbean 0.157 (0.132 to 0.181) <0.0001 0.124 (0.099 to 0.148) <0.0001 
South Asian 0.052 (0.001 to 0.103) 0.045 0.057 (0.007 to 0.107) 0.027 
East Asian 0.042 (-0.024 to 0.109) 0.210   
Mixed 0.018 (-0.044 to 0.079) 0.575   
Conception     
Spontaneous (reference) 1.000    
Assisted conception 0.008 (-0.050 to 0.065) 0.796   
Medical disorders     
Sickle cell trait 0.243 (0.183 to 0.302) <0.0001 0.187 (0.129 to 0.245) <0.0001 
Thyroid disorders 8.9e-05 (-0.083 to 0.084) 0.998   
Chronic hypertension 0.085 (0.008 to 0.162) 0.030   
Autoimmune disease 0.271 (-0.050 to 0.591) 0.098   
Diabetes mellitus -0.007 (-0.119 to 0.105) 0.902   
Family history     
History of preeclampsia in mother -0.002 (-0.061 to 0.057) 0.944   
Diabetes mellitus -0.003 (-0.027 to 0.022) 0.829   
Obstetric history     
Nulliparous  1.00    
Parous – previous preeclampsia 0.040 (-0.016 to 0.096) 0.165   
Parous – previous gestational diabetes 0.154 (0.032 to 0.275) 0.013   
Current pregnancy complication     
Preeclampsia 0.027 (-0.045 to 0.098) 0.466   
Gestational diabetes 0.024 (-0.038 to 0.087) 0.447   
Fetal growth restriction -0.002 (-0.038 to 0.033) 0.899   
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Table 3. Univariable and multivariable regression regression analysis to examine factors 1 
from maternal and pregnancy characteristics affecting the concentration of log10 transformed 2 
fibrin monomer complex 3 
 4 
 5 
CI=confidence interval  6 
 7 
 8 
 9 
 10 
Variable 
Univariable analysis Multivariable analysis 
Estimate (95% CI) P value Estimate (95% CI) P value 
 
    
Maternal characteristics     
Maternal age in years - 32 -0.001 (-0.003 to 0.001) 0.339   
Maternal weight in Kg - 69 0.001 (7.8e-05 to 0.002) 0.031 0.001 (2.3e-04 to 0.002) 0.012 
Maternal height in meters -1.64 0.099 (-0.076 to 0.274) 0.266   
Gestational age in weeks - 11 0.007 (-0.013 to 0.027) 0.468   
Cigarette smoker -0.023 (-0.066 to 0.020) 0.296   
Cocaine use -0.145 (-0.279 to -0.011) 0.034 -0.147 (-0.280 to -0.014) 0.030 
Racial origin     
Caucasian (reference) 1.000    
Afro-Caribbean 0.019 (-0.007 to 0.044) 0.149   
South Asian 0.011 (-0.042 to 0.064) 0.680   
East Asian -0.010 (-0.081 to 0.061) 0.780   
Mixed 0.054 (-0.015 to 0.124) 0.124   
Conception     
Spontaneous (reference) 1.000    
Assisted conception -0.030 (-0.086 to 0.026) 0.295   
Medical disorders     
Sickle cell trait -0.026 (-0.088 to 0.035) 0.405   
Thyroid disorders -0.036 (-0.127 to 0.054) 0.432   
Chronic hypertension -0.136 (-0.224 to -0.048) 0.002 -0.150 (-0.238 to -0.062) 0.001 
Autoimmune disease -0.312 (-0.712 to 0.089) 0.127   
Diabetes mellitus -0.136 (-0.288 to 0.016) 0.079   
Family history     
History of preeclampsia in mother 0.010 (-0.050 to 0.070) 0.740   
Diabetes mellitus -0.005 (-0.036 to 0.027) 0.776   
Obstetric history     
Nulliparous  1.000    
Parous – previous preeclampsia 0.017 (-0.037 to 0.071) 0.540   
Parous – previous gestational diabetes 0.032 (-0.066 to 0.130) 0.519   
Current pregnancy complication     
Preeclampsia -0.018 (-0.089 to 0.053) 0.616   
Gestational diabetes 0.022 (-0.043 to 0.087) 0.503   
Fetal growth restriction -0.014 (-0.049 to 0.022) 0.447   
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Figure legends 1 
 2 
Figure 1. Association between log10 D-dimer with gestational age (left), maternal weight 3 
(middle) and smoking, racial origin and medical history of sickle cell trait (right). Association 4 
between log10 fibrin monomer complexes with cocaine use and medical history of chronic 5 
hypertension (right). 6 
 7 
 8 
 9 
Figure 2. Distribution of D-dimer (left) and fibrin monomer (right) multiple of the median 10 
values (MoM) with the median, 5th and 95th percentiles. 11 
 12 
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